Pediatric Oncology | Specialty

Palliative Care Opportunities Missed in Pediatric Hematology/Oncology

November 30th 2017

Physicians are missing opportunities to refer pediatric patients with hematologic malignancies to palliative care at the end of life, and those who are admitted to palliative care tend to have very advanced disease.

CD200, CD56 Expression Predict Poor Prognosis in Pediatric B-ALL

November 29th 2017

Children with B-cell acute lymphoblastic leukemia who were positive for CD200 and/or CD56 expression had significantly poorer overall survival and disease-free survival.

Multimodality Treatment Linked to High OS Rate in Pediatric RMS of Head and Neck

November 29th 2017

An adjusted combination of chemotherapy, radiation therapy, and surgery induced a 5-year overall survival rate of 91.3% in pediatric patients with rhabdomyosarcomas of the head and neck.

Absolute Risk for Developing Most STS Low in Childhood Cancer Survivors

November 29th 2017

While survivors of childhood cancers are at increased risk for developing soft-tissue sarcomas compared with the general population, the absolute risk for developing STS is low except for leiomyosarcoma after retinoblastoma.

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

November 28th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Alternative Treatment Options Emerging for Relapsed Pediatric Patients With ALL

November 27th 2017

Susan R. Rheingold, MD, discusses the impact of CAR T-cell therapy on patients with ALL and options for patients who relapse on treatment.

Nilotinib Approved in Europe for Subset of Pediatric CML

November 21st 2017

The European Commission has approved nilotinib (Tasigna) for the treatment of pediatric patients with Ph+ chronic myeloid leukemia in the chronic phase.

MRD, Genetic Classification Provide More Accurate Risk Stratification in Pediatric ALL

November 17th 2017

Investigators working in the UK and Europe found a correlation between minimal residual disease kinetics and risk for relapse in pediatric patients with acute lymphoblastic leukemia.

CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia

November 16th 2017

Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Dr. Daver on CAR T-Cell Therapy Approval in Pediatric ALL

November 16th 2017

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the approval of a chimeric antigen receptor (CAR) T-cell therapy in pediatric acute lymphoblastic leukemia.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017